HOWL

Werewolf Therapeutics, Inc. - Common Stock (HOWL)

About Werewolf Therapeutics, Inc. - Common Stock (HOWL)

Werewolf Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. The firm offers Predator Technology which focuses on immune targeting and activation. The company was founded by Daniel J. Hicklin, Patrick A. Baeuerle, and Luke B. Evnin on October 19, 2017 and is headquartered in Watertown, MA.

Details

Daily high

$0.99

Daily low

$0.96

Price at open

$0.98

52 Week High

$2.38

52 Week Low

$0.27

Market cap

46.9M

Dividend yield

Volume

476,601

Avg. volume

2.6M

P/E ratio

-1.31

Werewolf Therapeutics, Inc. - Common Stock News